DEFA14A: ModivCare Secures $105 Million in Financing and Appoints Chief Transformation Officer Amid Strategic Overhaul

ModivCare obtains $105 million in incremental financing, appoints a Chief Transformation Officer, and initiates a strategic review of assets to bolster its financial position and future growth.

Summary

• ModivCare has secured $105 million in incremental financing through a $75 million term loan and a $30 million commitment from Coliseum Capital Management to purchase new second lien notes, pending stockholder approval.
• The company has appointed Chad Shandler as Chief Transformation Officer to focus on strategic and operational improvements.
• ModivCare is undertaking a strategic review of its assets to maximize shareholder value, potentially including asset sales.
• The existing credit agreement has been amended to provide covenant relief, including a covenant holiday and resetting financial ratios for specific periods.
• The company has withdrawn its previously stated revenue and adjusted EBITDA guidance for fiscal year 2024 and adjusted EBITDA growth for fiscal year 2025.
• The incremental term loan is priced at SOFR + 750 bps with a 1.00% SOFR floor and a maturity date of January 10, 2026.
• The company's lenders have agreed to reduce the minimum liquidity covenant from $75 million to $25 million, tested weekly through April 11, 2025, monthly through June 30, 2025, and quarterly thereafter.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has secured financing and is taking steps to improve its operations, the withdrawal of guidance and high interest rate on the term loan raise concerns.

Positives

• The $105 million in financing provides additional resources to focus on long-term strategic priorities.
• The appointment of a Chief Transformation Officer is expected to drive strategic and operational excellence.
• The strategic review of assets could potentially maximize shareholder value.
• Covenant relief provides increased financial flexibility in the near term.

Negatives

• The company has withdrawn its previously stated revenue and adjusted EBITDA growth guidance.
• The incremental term loan has a high interest rate (SOFR + 750 bps) and a relatively short maturity (January 10, 2026).
• The transaction with Coliseum is subject to stockholder approval, which is not guaranteed.
• The company is subject to a cash variance compliance test with respect to aggregate disbursements and aggregate receipts.

Risks

• The company may not be successful in implementing its business plan.
• The company has a history of operating losses and negative cash flow.
• The company may not be able to generate sufficient cash to service all of its indebtedness.
• The company has experienced significant turnover in its senior management team.
• Negotiations regarding new capital investment may consume a substantial portion of the time and attention of the company's management.

Future Outlook

The company is focused on strengthening its financial foundation, enhancing operational performance, and positioning itself for sustainable growth through strategic initiatives and a review of its assets.

Management Comments

• Heath Sampson, Chief Executive Officer and President of ModivCare, stated that the financing highlights broad-based support from stakeholders and provides additional resources to focus on long-term strategic priorities.
• Leslie Norwalk, Interim Chair of the Board, stated that the company has worked diligently to strengthen its financial foundation and remains focused on improving operational performance with a view toward long-term growth.

Industry Context

The announcement reflects a trend in the healthcare services industry where companies are seeking to optimize their capital structure and improve operational efficiencies in response to changing market conditions and business challenges.

Comparison to Industry Standards

• The interest rate on the incremental term loan (SOFR + 750 bps) is relatively high, reflecting the company's current financial situation and the risk associated with the investment.
• The covenant relief obtained by ModivCare is a common strategy for companies facing financial challenges, providing them with more flexibility to navigate difficult periods.
• The strategic review of assets is a typical approach for companies seeking to unlock value and improve their financial performance, similar to actions taken by other companies in the healthcare sector.

Management Changes

Related Party Transactions

• Coliseum Capital Management, an existing investor, has committed $30 million to purchase new second lien senior notes, subject to stockholder approval.

Stakeholder Impact

• Shareholders: The strategic review of assets and efforts to improve operational performance are intended to maximize shareholder value.
• Employees: The company is taking steps to transform its business, which may impact employees.
• Customers: The company is focused on continuing to provide a high level of service for members.
• Creditors: The company has obtained covenant relief and additional financing from its lenders.

Next Steps

• The company will seek stockholder approval for the transaction with Coliseum Capital Management.
• The company will appoint three new independent directors to the Board.
• The company will continue to implement its strategic initiatives and conduct a review of its assets.

Key Dates

Keywords

financing, chief transformation officer, strategic review, covenant relief, EBITDA, term loan, liquidity, second lien notes, senior notes, ModivCare